Traditionally, clinicians utilized alpha-fetoprotein (AFP) and AFP-L3 (a glycoform of AFP) as HCC biomarkers in most developing countries7,9; however, these biomarkers have no reliability, sufficient sensitivity, and specificity8. The gene discussed is AFP; the disease is hepatocellular carcinoma.